The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it dow
An alternative to epinephrine autoinjectors that can be delivered by a nasal spray is close to approval in Europe after being recommended for approval by the EMA’s human medicines committee
Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chr
Going against the advice of its own advisors, the European Commission has said that PTC Therapeutics’ Translarna therapy for Duchenne muscular dystrophy (DMD) should stay
Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer, after a recommenda
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh